YIBAI PHARMACEUTICAL(SH:600594) Xin Lang Cai Jing·2025-10-30 04:28Core Insights - Yibai Pharmaceutical (600594.SH) reported a total operating revenue of 1.447 billion yuan for Q3 2025, a decrease of 267 million yuan compared to the same period last year, representing a year-on-year decline of 15.59% [1] - The company recorded a net profit attributable to shareholders of -86.56 million yuan, ranking 52nd among disclosed peers [1] - The net cash inflow from operating activities was 204 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 34.46%, ranking 38th among disclosed peers, an increase of 1.10 percentage points compared to the same period last year [3] - The latest gross profit margin is 60.32%, a decrease of 0.33 percentage points from the previous quarter and a decline of 1.87 percentage points year-on-year [3] - The latest return on equity (ROE) is -3.60%, ranking 50th among disclosed peers [3] - The diluted earnings per share (EPS) is -0.11 yuan, ranking 49th among disclosed peers [3] - The total asset turnover ratio is 0.36 times, a decrease of 0.03 times year-on-year, representing a decline of 6.80% [3] - The inventory turnover ratio is 1.00 time, ranking 45th among disclosed peers, a decrease of 0.14 times year-on-year, representing a decline of 12.46% [3] Shareholder Information - The number of shareholders is 49,100, with the top ten shareholders holding a total of 257 million shares, accounting for 32.44% of the total share capital [3] - The top ten shareholders and their holdings are as follows: 1. Dou Qiling: 23.4 million shares 2. Chang Liangxing: 2.99 million shares 3. Zhang Sufen: 1.92 million shares 4. Guangzhou Zhujiang Development Group Co., Ltd.: 1.10 million shares 5. Lang Hongping: 1.00 million shares 6. He Xiaohong: 0.49 million shares 7. He Zhongping: 0.48 million shares 8. Chen Guangqi: 0.45 million shares 9. Nian Lei: 0.32 million shares 10. Dai Wenping: 0.28 million shares [3]